Avricore is shifting focus to the rapidly expanding UK healthcare market and concluding its Canadian pharmacy partnership with Shoppers Drug Mart (as of July 2025). The company expanded HealthTab into pharmacies in North Central London (July 2025), making it the second NHS Integrated Care Board to adopt the platform.
Cyborg Score Rationale
Avricore achieved profitability in Q1 2024 and maintains continued growth, but operates as a micro-cap OTC stock with limited market liquidity. The company is executing a strategic geographic pivot to the UK market, signaling confidence in international expansion but also indicating challenges in the Canadian market.
Top Insights
Company reported first period of net profitability in Q1 2024
Strategic shift from Canadian to UK market reflects geographic reorientation (July 2025)
HealthTab platform gaining traction in NHS integrated care settings with multi-board adoption
Ultra-low market cap ($4.0M) and minimal trading volume indicate early-stage liquidity constraints
Named Competitors
GRAIL — Early cancer detection testing
Guardant Health — Blood-based liquid biopsy diagnostics
CVS Health Pharmacist Services — Pharmacy-based clinical services
Recent Developments
(June 2025) Rodger Seccombe appointed CEO
(July 2025) HealthTab platform expanded into North Central London pharmacies as second NHS ICB adoption
(July 2025) Strategic pivot to UK healthcare market; partnership with Shoppers Drug Mart being concluded
(June 2024) Q1 2024 net profitability achieved
Open the full interactive Avricore Health Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.